Brief: Neuroscientific Biopharmaceuticals Says Net After-Tax Loss For Year A$10.5 Million
30/08/2022 24:34
Aug 30 (Reuters) - NeuroScientific Biopharmaceuticals Ltd
NSB.AX :
* NET AFTER-TAX LOSS FOR YEAR A$10.5 MILLION
Source text for Eikon: ID:nASX2VCWYX
Further company coverage: NSB.AX
Recent news on Neuroscientific Biopharmaceuticals
See all newsBrief: Neuroscientific Biopharmaceuticals Appoints Chris Knee As CFO
Brief: Neuroscientific Biopharmaceuticals Seeks Trading Halt
Australia's NeuroScientific Biopharmaceuticals surges on positive clinical results
Brief: Neuroscientific Biopharmaceuticals Requests Trading Halt
Brief: Neuroscientific Biopharmaceuticals Appoints Nathan Smith As CEO